Vasopressin compared with norepinephrine augments the decline of plasma cytokine levels in septic shock

American Journal of Respiratory and Critical Care Medicine

Volumn 188, Issue 3, 2013, Pages 356-364

  Russell, James A ^a,b,e   Fjell, Chris ^a   Hsu, Joseph L ^c,d   Lee, Terry ^b   Boyd, John ^a,b   Thair, Simone ^a   Singer, Joel ^b   Patterson, Andrew J ^c,d   Walley, Keith R ^a,b  

^a The James Hogg iCAPTURE Centre for Cardiovascular and Pulmonary Research   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Department of Anesthesia and Medicine ^*  (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e ST PAUL S HOSPITAL   (Canada)

Author keywords

Chemokines; Cytokines; Norepinephrine; Septic shock; Vasopressin

Indexed keywords

ALPHA2 INTERFERON; CREATINE; CYTOKINE; EOTAXIN; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; INTERLEUKIN 9; LACTIC ACID; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; NORADRENALIN; UNINDEXED DRUG; VASOPRESSIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; FEMALE; HUMAN; INNATE IMMUNITY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SEPTIC SHOCK; SURVIVOR; THROMBOCYTE COUNT;

ADOLESCENT; ADRENERGIC ALPHA-AGONISTS; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CYTOKINES; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NOREPINEPHRINE; SHOCK, SEPTIC; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES; VASOCONSTRICTOR AGENTS; VASOPRESSINS; YOUNG ADULT;

EID: 84881173520     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201302-0355OC     Document Type: Article

References (38)

1. Russell JA. Management of sepsis. N Engl J Med 2006;355:1699-1713.
2. Jansen PM, Boermeester MA, Fischer E, de Jong IW, van der Poll T, Moldawer LL, Hack CE, Lowry SF. Contribution of interleukin-1 to activation of coagulation and fibrinolysis, neutrophil degranulation, and the release of secretory-type phospholipase A2 in sepsis: Studies in nonhuman primates after interleukin-1 alpha administration and during lethal bacteremia. Blood 1995;86:1027-1034.
3. van der Poll T, Fischer E, Coyle SM, Van Zee KJ, Pribble JP, Stiles DM, Barie PS, Buurman WA, Moldawer LL, Lowry SF. Interleukin-1 contributes to increased concentrations of soluble tumor necrosis factor receptor type I in sepsis. J Infect Dis 1995;172:577-580.
4. van der Poll T, Lowry SF. Tumor necrosis factor in sepsis: Mediator of multiple organ failure or essential part of host defense? Shock 1995;3:1-12.
5. Pinsky MR, Vincent JL, Deviere J, Alegre M, Kahn RJ, Dupont E. Serum cytokine levels in human septic shock: Relation to multiplesystem organ failure and mortality. Chest 1993;103:565-575.
6. Bozza FA, Salluh JI, Japiassu AM, Soares M, Assis EF, Gomes RN, Bozza MT, Castro-Faria-Neto HC, Bozza PT. Cytokine profiles as markers of disease severity in sepsis: A multiplex analysis. Crit Care 2007;11:R49.
7. Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 2003;101:3765-3777.
8. Casanova JL, Abel L. The human model: A genetic dissection of immunity to infection in natural conditions. Nat Rev Immunol 2004;4:55-66.
9. Ringnér M. What is principal component analysis? Nat Biotechnol 2008; 26:303-304.
10. Zhao L, Brinton RD. Suppression of proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha in astrocytes by a V1 vasopressin receptor agonist: A cAMP response element-binding protein-dependent mechanism. J Neurosci 2004;24:2226-2235.
11. Boyd JH, Holmes CL, Wang Y, Roberts H, Walley KR. Vasopressin decreases sepsis-induced pulmonary inflammation through the V2R. Resuscitation 2008;79:325-331.
12. Chassin C, Hornef MW, Bens M, Lotz M, Goujon JM, Vimont S, Arlet G, Hertig A, Rondeau E, Vandewalle A. Hormonal control of the renal immune response and antibacterial host defense by arginine vasopressin. J Exp Med 2007;204:2837-2852.
13. McNamee EN, Griffin EW, Ryan KM, Ryan KJ, Heffernan S, Harkin A, Connor TJ. Noradrenaline acting at beta-adrenoceptors induces expression of IL-1beta and its negative regulators IL-1ra and IL-1RII, and drives an overall anti-inflammatory phenotype in rat cortex. Neuropharmacology 2010;59:37-48.
14. McNamee EN, Ryan KM, Griffin EW, González-Reyes RE, Ryan KJ, Harkin A, Connor TJ. Noradrenaline acting at central beta-adrenoceptors induces interleukin-10 and suppressor of cytokine signaling-3 expression in rat brain: Implications for neurodegeneration. Brain Behav Immun 2010; 24:660-671.
15. Briest W, Rassler B, Deten A, Leicht M, Morwinski R, Neichel D, Wallukat G, Ziegelhöffer T, Zimmer HG. Norepinephrine-induced interleukin-6 increase in rat hearts: Differential signal transduction in myocytes and non-myocytes. Pflugers Archiv 2003;446:437-446.
16. Briest W, Elsner C, Hemker J,Müller-Strahl G, Zimmer HG. Norepinephrineinduced expression of cytokines in isolated biventricular working rat hearts. Mol Cell Biochem 2003;245:69-76.
17. Torres KC, Antonelli LR, Souza AL, Teixeira MM, Dutra WO, Gollob KJ. Norepinephrine, dopamine and dexamethasone modulate discrete leukocyte subpopulations and cytokine profiles from human PBMC. J Neuroimmunol 2005;166:144-157.
18. Russell JA, Walley KR, Singer J, Gordon AC, Hébert PC, Cooper DJ, Holmes CL, Mehta S, Granton JT, Storms MM, et al.; VASST Investigators. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008;358:877-887.
19. Glass DC, Gray CN. Estimating mean exposures from censored data: Exposure to benzene in the Australian petroleum industry. Ann Occup Hyg 2001;45:275-282.
20. Mira JP, Cariou A, Grall F, Delclaux C, Losser MR, Heshmati F, Cheval C, Monchi M, Teboul JL, Riché F, et al. Association of TNF2, a TNFalpha promoter polymorphism, with septic shock susceptibility and mortality: A multicenter study. JAMA 1999;282:561-568.
21. Boyd JH, Forbes J, Nakada TA, Walley KR, Russell JA. Fluid resuscitation in septic shock: A positive fluid balance and elevated central venous pressure are associated with increased mortality. Crit Care Med 2011;39:259-265.
22. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M; Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368-1377.
23. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000;342:1301-1308.
24. Ranieri VM, Suter PM, Tortorella C, De Tullio R, Dayer JM, Brienza A, Bruno F, Slutsky AS. Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: A randomized controlled trial. JAMA 1999;282:54-61.
25. Kumar A. Early antimicrobial therapy in severe sepsis and septic shock. Curr Infect Dis Rep 2010;12:336-344.
26. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, et al.; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344: 699-709.
27. Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, Gårdlund B, Marshall JC, Rhodes A, Artigas A, et al.; PROWESSSHOCK Study Group. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012;366:2055-2064.
28. Herbertson MJ, Werner HA, Goddard CM, Russell JA, Wheeler A, Coxon R, Walley KR. Anti-tumor necrosis factor-alpha prevents decreased ventricular contractility in endotoxemic pigs. Am J Respir Crit Care Med 1995;152:480-488.
29. Merx MW, Weber C. Sepsis and the heart. Circulation 2007;116:793-802.
30. Kumar A, Thota V, Dee L, Olson J, Uretz E, Parrillo JE. Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med 1996;183:949-958.
31. Brady AJ, Poole-Wilson PA, Harding SE, Warren JB. Nitric oxide production within cardiac myocytes reduces their contractility in endotoxemia. Am J Physiol 1992;263:H1963-H1966.
32. Vincent JL, Zhang H, Szabo C, Preiser JC. Effects of nitric oxide in septic shock. Am J Respir Crit Care Med 2000;161:1781-1785.
33. Hinder F, Stubbe HD, Van Aken H, Waurick R, Booke M, Meyer J. Role of nitric oxide in sepsis-associated pulmonary edema. Am J Respir Crit Care Med 1999;159:252-257.
34. Helmy A, Antoniades CA, Guilfoyle MR, Carpenter KL, Hutchinson PJ. Principal component analysis of the cytokine and chemokine response to human traumatic brain injury. PLoS ONE 2012;7:e39677.
35. Nieman G, Brown D, Sarkar J, Kubiak B, Ziraldo C, Dutta-Moscato J, Vieau C, Barclay D, Gatto L, Maier K, et al. A two-compartment mathematical model of endotoxin-induced inflammatory and physiologic alterations in swine. Crit Care Med 2012;40:1052-1063.
36. Hashemi S, Palmer DS, Aye MT, Ganz PR. Platelet-activating factor secreted by DDAVP-treated monocytes mediates von Willebrand factor release from endothelial cells. J Cell Physiol 1993;154:496-505.
37. Campanella GS, Colvin RA, Luster AD. CXCL10 can inhibit endothelial cell proliferation independently of CXCR3. PLoS ONE 2010;5: E12700.
38. Feldman ED, Weinreich DM, Carroll NM, Burness ML, Feldman AL, Turner E, Xu H, Alexander HR Jr. Interferon gamma-inducible protein 10 selectively inhibits proliferation and induces apoptosis in endothelial cells. Ann Surg Oncol 2006;13:125-133.